Polycarbophil calcium

Clinical data
Pregnancy
category|

* US: C (Risk not ruled out)

Routes of
use| Oral (tablets)
External links
AHFS/Drugs.com| Multum Consumer Information
Legal
Legal status|

* US: OTC

Chemical and physical data
Formula| (C3H3Ca1/2O2)a(C6H10O2)b

Polycarbophil calcium is a medication used as a stool stabilizer.

It is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol, with calcium as a counter-ion.

## Contents

* 1 Medical uses
* 2 Society and culture
* 2.1 Cost
* 3 References
* 4 Further reading
* 5 External links

## Medical uses[edit | edit source]

It is used as stool stabilizer to treat constipation, diarrhea and abdominal discomfort. Bulk laxatives absorb liquid in the intestines and swell to form a soft bulky stool. The bulky mass stimulates the intestinal muscles, speeding stool transit time through the colon. Results usually occur within 12 to 72 hours. Calcium polycarbophil will not work without increased fluid intake.

A different representation: polyacrylic acid residues are shown in red, residues of the cross-linker divinyl glycol (3,4-dihydroxy-1,5-hexadiene) in blue.

Calcium polycarbophil has been marketed as an over-the-counter agent used for treating functional bowel disorder and as a bulk-producing agent.

A study looked at the effects of calcium polycarbophil on general irritable bowel syndrome (IBS) symptoms. Fourteen patients with IBS-diarrhea and twelve with IBS-constipation were given calcium polycarbophil for eight weeks and their colon transit times were measured with radiopaque markers in the colon. The patients with diarrhea reported fewer bowel movements, more solid stools and reduced abdominal pain. Patients with constipation reported more frequent bowel movements, looser stools and less pain.[1]

The human stomach presents a mild acidic environment due to the presence of HCl. Polycarbophil absorbs about ten times its own weight of water under acidic conditions, but the swelling ratio markedly increases at above pH 4.0 and reaches 70 times the initial weight under pH-neutral conditions. The swelling of polycarbophil is not affected by non-ionic osmolarity, but by ionic strength, showing a decrease with increase of ionic strength. Monovalent metal ions such as sodium and potassium ions in gastrointestinal fluid do not reduce the equilibrium swelling of polycarbophil, but divalent ions such as calcium and magnesium ions do. However, calcium ions only slightly reduce the equilibrium swelling under sodium-rich conditions.[2]

## Society and culture[edit | edit source]

### Cost[edit | edit source]

In the U.S. the cost for 0.12 bottle, $4 (USD) for 500 tablets.[3]

* Polycarbophil calcium costs (US)

* Polycarbophil calcium prescriptions (US)

## References[edit | edit source]

1. ↑ Chiba T, Kudara N, Sato M, Chishima R, Abiko Y, Inomata M, et al. (2005). "Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil". Hepato-Gastroenterology. 52 (65): 1416–20. PMID 16201086.
2. ↑ Shibata C, Funayama Y, Fukushima K, Takahashi K, Ogawa H, Haneda S, et al. (June 2007). "Effect of calcium polycarbophil on bowel function after restorative proctocolectomy for ulcerative colitis: a randomized controlled trial". Digestive Diseases and Sciences. 52 (6): 1423–6. doi:10.1007/s10620-006-9270-6. PMID 17394081. S2CID 22022224.
3. ↑ "Compare Calcium Polycarbophil prices and find coupons that could save you up to 80% instantly at pharmacies near you such as CVS, Walgreens, Walmart, and many more". www.webmd.com. Archived from the original on 29 August 2021. Retrieved 25 March 2021.

## Further reading[edit | edit source]

* Saito T, Mizutani F, Iwanaga Y, Morikawa K, Kato H (June 2002). "Laxative and anti-diarrheal activity of polycarbophil in mice and rats". Japanese Journal of Pharmacology. 89 (2): 133–41. doi:10.1254/jjp.89.133. PMID 12120755.
* Torii A, Toda G (May 2004). "Management of irritable bowel syndrome". Internal Medicine. 43 (5): 353–9. doi:10.2169/internalmedicine.43.353. PMID 15206545.[permanent dead link]
* Paterson WG, Thompson WG, Vanner SJ, Faloon TR, Rosser WW, Birtwhistle RW, et al. (July 1999). "Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants". CMAJ. 161 (2): 154–60. PMC 1230466. PMID 10439825.

## External links[edit | edit source]

Identifiers:|

* ATC code:

* A06AC08 (WHO)

* CAS Number: 9003-97-8 N
* ChemSpider:

* none

* UNII:

* W25LM17A4W

* KEGG:

* D03306 N

|

* v
* t
* e

Drugs for constipation (laxatives and cathartics) (A06)

Stool softeners|

* Docusate

Stimulant laxatives|

* Bisacodyl
* Bisoxatin
* Cascara
* Castor oil
* Dantron
* Oxyphenisatine
* Phenolphthalein
* Senna glycosides
* Sodium picosulfate

Bulk-forming laxatives|

* Dietary fiber
* Ethulose
* Ispaghula
* Methylcellulose
* Polycarbophil calcium
* Sterculia
* Triticum

Lubricant laxatives|

* Liquid paraffin
* Mineral oil
* White petrolatum (petroleum jelly)

Osmotic laxatives|

* Lactitol
* Lactulose
* Laminarid
* Magnesium carbonate
* Magnesium citrate
* Magnesium hydroxide (milk of magnesia)
* Magnesium oxide
* Magnesium peroxide
* Magnesium sulfate
* Mannitol
* Pentaerythritol
* Polyethylene glycol (macrogol)
* Sodium phosphate
* Sodium sulfate
* Sodium tartrate
* Sorbitol

Enemas|

* Bisacodyl
* Dantron
* Glycerol
* Oil
* Sodium laurilsulfate
* Sodium lauryl sulfoacetate
* Sodium phosphate
* Sorbitol

Opioid antagonists|

* Naloxone (Oxycodone/naloxone)
* PAMORAs
* Alvimopan
* Axelopran
* Bevenopran
* Methylnaltrexone
* Naldemedine
* Naloxegol

Others|

* Linaclotide
* Lubiprostone
* Oxyphenisatine
* Plecanatide
* Prucalopride
* Tegaserod
* Tenapanor
* Ulimorelin

*[US]: United States
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template